Vabysmo is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Vabysmo is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameVabysmo
Authorized genericfaricimab
Regular genericfaricimab
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Vabysmo?
The original
–
–

Brand nameThe maker’s card

Genentech Ophthalmology Co-pay Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a treatment

The card takes up to $15,000 a year off your co-pay.

Sign up on vabysmo.com 

Or call 1-833-393-4363.

In the maker’s words

“With the Genentech Ophthalmology Co-pay Program, eligible patients with commercial insurance could pay as little as $0 per treatment.”

From the maker’s offer on vabysmo.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Vabysmo itself, from the same company, sold without the brand name, and usually for less. For now Vabysmo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Vabysmo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
  • Diabetic Macular Edema (DME)
  • Macular Edema Following Retinal Vein Occlusion (RVO)

Source: the FDA label for Vabysmo (Genentech, Inc.), April 15, 2026. Full label on DailyMed 

Good to know